Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
IgG4-Related Disease Clinical Trials 2024: EMA, PDMA, FDA
The article highlights the ongoing clinical trials and developments in the treatment of IgG4-Related Disease (IgG4-RD), a chronic immune-mediated condition affecting multiple organs. Key companies like Amgen, Sanofi, and Zenas Biopharma are advancing therapies such as UPLIZNA and obexelimab, with significant progress reported in Phase III trials. The disease's complexity, involving fibrosis and inflammation, underscores the importance of early diagnosis and treatment, primarily with corticosteroids or immunosuppressive agents for refractory cases.
Rilzabrutinib & First Biosimilar Golimumab Among New EU Filings
Sanofi’s rilzabrutinib and Alvotech/Advanz Pharma’s golimumab (AVT05) are among five new entries on the European Medicines Agency’s latest monthly list of products under review. Both drugs are investigational and unapproved globally.
Sanofi launches world's first modular concept manufacturing facility to Singapore
Sanofi inaugurated Modulus, a state-of-the-art, sustainable biopharmaceutical manufacturing facility in Singapore, leveraging a modular concept for flexible production of next-generation vaccines and biological medicines, aiming to be fully operational by mid-2026.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to host virtual investor event on Jan 8, 2025, discussing initial data from Phase 1 T-cell engagers VIR-5818 and VIR-5500, and updates on the PRO-XTEN™ platform.
Patsnap Launches Hiro Life Sciences – Revolutionizing Drug Research with Generative AI
Patsnap launches Hiro Life Sciences (Hiro LS), an AI assistant using PharmaGPT to accelerate biopharmaceutical research by integrating generative AI with domain-specific data, offering real-time insights, seamless integration, enhanced collaboration, and secure interactions.
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals
Hemophilia B market to grow significantly by 2034, driven by gene therapies like HEMGENIX and BEQVEZ, priced at $3.5 million each. Key companies include Centessa Pharmaceuticals, Sanofi, Pfizer, and Novo Nordisk. Market dynamics influenced by increasing prevalence, prophylactic treatment focus, and pipeline advancements.
SWOT analysis: stock poised for growth amid clinical progress
Vir Biotechnology, a clinical-stage immunology company, focuses on treating serious infectious diseases, particularly hepatitis delta virus (HDV) and hepatitis B virus (HBV). Recent positive Phase 2 data for HDV and HBV treatments have advanced the HDV program to Phase 3 trials. Despite negative earnings per share projections, Vir's strong balance sheet supports long-term growth. The company's strategic partnerships and pipeline expansion into T-cell engagers offer potential market opportunities, though clinical trial risks and commercialization challenges remain.
© Copyright 2025. All Rights Reserved by MedPath